ABSTRACT
BACKGROUND: Hidradenitis suppurativa (HS) fistulas are likely to persist without surgical intervention. Hypertonic saline (HTS), a venous sclerosant, disrupts the endothelial lining leading to occlusion and fibrosis when used for venous insufficiency. OBJECTIVE: To evaluate the efficacy and tolerability of HTS sclerotherapy for HS fistulas. METHODS AND MATERIALS: This Institutional review board-approved, nonrandomized, clinical trial included adult patients with a diagnosis of HS and at least one confirmed HS fistula who underwent HTS injections into their fistulas every two weeks followed by a 4-week follow-up period. The study was performed from 2016 to 2019 at two academic outpatient dermatology clinics in Boston, MA. Primary outcomes were physician-assessed improvement of HS fistula characteristics between final and baseline visits and physician-assessed HS improvement during course of study. RESULTS: Overall, 21 patients participated. Physician-assessed overall HS improvement was significant between Visits 2 and 3 (p = .036). Drainage (p = .035), erythema (p = .008), and swelling (p = .025) demonstrated statistically significant improvement from baseline to final visit. Dermatology life quality index scores significantly improved from baseline to Visit 2 (p = .0005), Visit 3 (p = .0008), and final visit (p = .011). Numeric rating scale stinging scores increased with sclerosant volume. CONCLUSION: This study demonstrated physician-reported and patient-reported improvement in fistulas following serial HTS injections. HTS injections were well tolerated.
Subject(s)
Hidradenitis Suppurativa , Adult , Hidradenitis Suppurativa/diagnosis , Hidradenitis Suppurativa/drug therapy , Humans , Pilot Projects , Prospective Studies , Quality of Life , Sclerosing Solutions/therapeutic use , Severity of Illness Index , Treatment OutcomeABSTRACT
BACKGROUND: Patients with skin of color are at risk for skin cancer, pigmentary disorders, and photo-exacerbated conditions but find it challenging to use sunscreens on the market that leave an obvious residue on their skin. OBJECTIVE: The objective of this study was to examine sunscreen recommendations from the popular press and from practicing dermatologists for patients with skin of color. METHODS: We queried the Google search engine with the following search terms: "Sunscreen" with "skin of color," "dark skin," "black skin." For comparison, we also searched for "sunscreen" with "white skin," "pale skin," and "fair skin." We conducted an anonymous survey regarding sunscreen recommendations among dermatology trainees and board-certified dermatologists. RESULTS: Websites with recommendations on sunscreens for patients with skin of color compared with sunscreens for white or fair skin were more likely to recommend chemical sunscreens (70% vs. 36%) and more expensive products (median: $14 vs. $11.3 per ounce), despite the lower sun protection factor level (median: 32.5 vs. 50). In our survey study, dermatologists were overall cost-conscious and felt that sun protection factor level, broad spectrum (ultraviolet A/B protection), and price were the most important features of sunscreens for their patients. Cosmetic elegance was deemed least important. Dermatologists overall counseled patients with skin of color less on sunscreen use, and 42.9% reported that they either never, rarely, or only sometimes take patients' skin type into account when making sunscreen recommendations. CONCLUSION: These data represent an area for growth within dermatology to improve culturally competent care by gaining familiarity with sunscreen types and formulations that are geared toward patients with skin of color.
Subject(s)
COVID-19/epidemiology , Dermatologic Surgical Procedures , Pandemics , Practice Patterns, Physicians' , Skin Neoplasms/surgery , Aged , Dermatologic Surgical Procedures/statistics & numerical data , Humans , Massachusetts/epidemiology , Mohs Surgery/statistics & numerical data , SARS-CoV-2 , TriageSubject(s)
Acne Vulgaris , Polycystic Ovary Syndrome , Acne Vulgaris/complications , Acne Vulgaris/drug therapy , Female , Hirsutism , Humans , Mineralocorticoid Receptor Antagonists , Polycystic Ovary Syndrome/complications , Polycystic Ovary Syndrome/drug therapy , Retrospective Studies , SpironolactoneABSTRACT
BACKGROUND: Methotrexate is an immunomodulatory therapy that may offer benefit to patients with hidradenitis suppurativa (HS). Despite its theoretical advantages, there is a paucity of available data regarding long-term methotrexate use in patients with HS. OBJECTIVE: This study aimed to assess whether methotrexate treatment leads to improvement in HS disease severity. METHODS: We conducted an institutional review board-approved, single-center, retrospective chart review of patients with HS who were treated with methotrexate between 2000 and 2018. Primary outcome measurements included the HS Physician's Global Assessment (HS PGA), Hurley staging, abscess count, fistula count, and inflammatory nodule count. RESULTS: A total of 29 patients were identified; 14 were excluded for reasons including never starting methotrexate and missing follow-up data. For remaining patients (nâ¯=â¯15), the average cumulative dose of methotrexate was 520.1â¯mg (range, 30-1665â¯mg) and the average length of treatment was 11.7â¯months (range, 1-38â¯months). Patients taking methotrexate as a primary therapy had a higher cumulative dose and length of treatment (520.13â¯mg; 14.6â¯months) compared with those taking biologics concomitantly (468.44â¯mg; 9.1â¯months). Patients using methotrexate as primary therapy demonstrated nonsignificant reductions in HS PGA, inflammatory nodule count, and abscess count. Patients on concomitant biologic therapy failed to demonstrate any change in HS PGA, inflammatory nodule count, and abscess count. LIMITATIONS: Limitations of the study include its retrospective nature, small sample size, length of time on methotrexate between groups, and homogeneity of the patient population. CONCLUSION: Methotrexate may represent an effective treatment option in older patients with lower body mass indices but fails to offer benefit in patients taking concurrent biologic therapy.